Arrhythmias & electrophysiologyCohort study
Impact of chronic obstructive pulmonary disease in patients with atrial fibrillation: an analysis from the GLORIA-AF registry
- Prospective registry cohort study
- global
Authors' conclusion
In AF patients, COPD was associated with differences in OAC treatment and use of other drugs; Patients with AF and COPD had worse outcomes, including higher mortality, MACE, and major bleeding.
Study context
- Population
- Patients with atrial fibrillation (AF) in the global GLORIA-AF registry
- Participants
- 36,263 patients
- Exposure
- Chronic obstructive pulmonary disease (COPD) vs no COPD in AF
- COPDn = 2,261
- Outcome
- Composite of:
- All-cause death
- MACE
Main finding
All-cause death and MACE
Adjusted hazard ratio
1.78
95% CI 1.58–2.00
COPD vs No COPD
aHR 1.78 (95% CI 1.58–2.00)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Oral anticoagulant (OAC) use
- COPD associated with higher OAC use, aOR
- 1.29 (1.13-1.47) (95% CI)
- adjusted
OAC discontinuation
- COPD associated with higher OAC discontinuation, aHR
- 1.12 (1.01-1.25) (95% CI)
- adjusted
Beta-blocker use
- COPD associated with less beta-blocker use, aOR
- 0.79 (0.72-0.87) (95% CI)
- COPD associated with less use of amiodarone and propafenone, and higher use of digoxin and verapamil/diltiazem
- adjusted
All-cause death
- COPD associated with all-cause death, aHR
- 2.01 (1.77-2.28) (95% CI)
- adjusted
MACE
- COPD associated with MACE, aHR
- 1.41 (1.18-1.68) (95% CI)
- adjusted
Safety
Major bleeding
- COPD associated with major bleeding, aHR
- 1.48 (1.16-1.88) (95% CI)
- adjusted
Original publication
Impact of chronic obstructive pulmonary disease in patients with atrial fibrillation: an analysis from the GLORIA-AF registry. Europace. Published 24 January 2024. doi:10.1093/europace/euae021
Summarised from the published abstract; every number is checked against it